Cargando…

Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities

INTRODUCTION: Many patients are referred to multiple sclerosis (MS) tertiary centers to manage brain white matter hyperintensities (WMH). Multiple diagnoses can match in such situations, and we lack proper tools to diagnose complex cases. OBJECTIVE: This study aimed to prospectively analyze and corr...

Descripción completa

Detalles Bibliográficos
Autores principales: Levraut, Michael, Landes, Cassandre, Mondot, Lydiane, Cohen, Mikael, Bresch, Saskia, Brglez, Vesna, Seitz-Polski, Barbara, Lebrun-Frenay, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990749/
https://www.ncbi.nlm.nih.gov/pubmed/35401550
http://dx.doi.org/10.3389/fimmu.2022.864133
_version_ 1784683439114420224
author Levraut, Michael
Landes, Cassandre
Mondot, Lydiane
Cohen, Mikael
Bresch, Saskia
Brglez, Vesna
Seitz-Polski, Barbara
Lebrun-Frenay, Christine
author_facet Levraut, Michael
Landes, Cassandre
Mondot, Lydiane
Cohen, Mikael
Bresch, Saskia
Brglez, Vesna
Seitz-Polski, Barbara
Lebrun-Frenay, Christine
author_sort Levraut, Michael
collection PubMed
description INTRODUCTION: Many patients are referred to multiple sclerosis (MS) tertiary centers to manage brain white matter hyperintensities (WMH). Multiple diagnoses can match in such situations, and we lack proper tools to diagnose complex cases. OBJECTIVE: This study aimed to prospectively analyze and correlate with the final diagnosis, cerebrospinal fluid (CSF) interleukin (IL)-1β, soluble IL-2 receptor (CD25), IL-6, IL-10, and kappa free light chains (KFLC) concentrations in patients presenting with brain WMH. METHODS: All patients over 18 years addressed to our MS tertiary center for the diagnostic workup of brain WMH were included from June 1, 2020, to June 1, 2021. Patients were separated into three groups—MS and related disorder (MSARD), other inflammatory neurological disorder (OIND), and non-inflammatory neurological disorder (NIND) groups—according to clinical presentation, MRI characteristics, and biological workup. RESULTS: A total of 176 patients (129 women, mean age 45.8 ± 14.7 years) were included. The diagnosis was MSARD (n = 88), OIND (n = 35), and NIND (n = 53). Median CSF KFLC index and KFLC intrathecal fraction (IF) were higher in MSARD than in the OIND and NIND groups; p < 0.001 for all comparisons. CSF CD25 and IL-6 concentrations were higher in the OIND group than in both the MSARD and NIND groups; p < 0.001 for all comparisons. KFLC index could rule in MSARD when compared to NIND (sensitivity, 0.76; specificity, 0.91) or OIND (sensitivity, 0.73; specificity, 0.76). These results were similar to those with oligoclonal bands (sensitivity, 0.59; specificity, 0.98 compared to NIND; sensitivity, 0.59; specificity, 0.88 compared to OIND). In contrast, elevated CSF CD25 and IL-6 could rule out MSARD when compared to OIND (sensitivity, 0.58 and 0.88; specificity, 0.95 and 0.74, respectively). DISCUSSION: Our results show that, as OCBs, KFLC biomarkers are helpful tools to rule in MSARD, whereas elevated CSF CD25 and IL-6 rule out MSARD. Interestingly, CSF IL-6 concentration could help identify neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and central nervous system (CNS) vasculitis. These results need to be confirmed within more extensive and multicentric studies. Still, they sustain that KFLC, CSF CD25, and CSF IL-6 could be reliable biomarkers in brain WMH diagnostic workup for differentiating MSARD from other brain inflammatory MS mimickers.
format Online
Article
Text
id pubmed-8990749
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89907492022-04-09 Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities Levraut, Michael Landes, Cassandre Mondot, Lydiane Cohen, Mikael Bresch, Saskia Brglez, Vesna Seitz-Polski, Barbara Lebrun-Frenay, Christine Front Immunol Immunology INTRODUCTION: Many patients are referred to multiple sclerosis (MS) tertiary centers to manage brain white matter hyperintensities (WMH). Multiple diagnoses can match in such situations, and we lack proper tools to diagnose complex cases. OBJECTIVE: This study aimed to prospectively analyze and correlate with the final diagnosis, cerebrospinal fluid (CSF) interleukin (IL)-1β, soluble IL-2 receptor (CD25), IL-6, IL-10, and kappa free light chains (KFLC) concentrations in patients presenting with brain WMH. METHODS: All patients over 18 years addressed to our MS tertiary center for the diagnostic workup of brain WMH were included from June 1, 2020, to June 1, 2021. Patients were separated into three groups—MS and related disorder (MSARD), other inflammatory neurological disorder (OIND), and non-inflammatory neurological disorder (NIND) groups—according to clinical presentation, MRI characteristics, and biological workup. RESULTS: A total of 176 patients (129 women, mean age 45.8 ± 14.7 years) were included. The diagnosis was MSARD (n = 88), OIND (n = 35), and NIND (n = 53). Median CSF KFLC index and KFLC intrathecal fraction (IF) were higher in MSARD than in the OIND and NIND groups; p < 0.001 for all comparisons. CSF CD25 and IL-6 concentrations were higher in the OIND group than in both the MSARD and NIND groups; p < 0.001 for all comparisons. KFLC index could rule in MSARD when compared to NIND (sensitivity, 0.76; specificity, 0.91) or OIND (sensitivity, 0.73; specificity, 0.76). These results were similar to those with oligoclonal bands (sensitivity, 0.59; specificity, 0.98 compared to NIND; sensitivity, 0.59; specificity, 0.88 compared to OIND). In contrast, elevated CSF CD25 and IL-6 could rule out MSARD when compared to OIND (sensitivity, 0.58 and 0.88; specificity, 0.95 and 0.74, respectively). DISCUSSION: Our results show that, as OCBs, KFLC biomarkers are helpful tools to rule in MSARD, whereas elevated CSF CD25 and IL-6 rule out MSARD. Interestingly, CSF IL-6 concentration could help identify neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and central nervous system (CNS) vasculitis. These results need to be confirmed within more extensive and multicentric studies. Still, they sustain that KFLC, CSF CD25, and CSF IL-6 could be reliable biomarkers in brain WMH diagnostic workup for differentiating MSARD from other brain inflammatory MS mimickers. Frontiers Media S.A. 2022-03-25 /pmc/articles/PMC8990749/ /pubmed/35401550 http://dx.doi.org/10.3389/fimmu.2022.864133 Text en Copyright © 2022 Levraut, Landes, Mondot, Cohen, Bresch, Brglez, Seitz-Polski and Lebrun-Frenay https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Levraut, Michael
Landes, Cassandre
Mondot, Lydiane
Cohen, Mikael
Bresch, Saskia
Brglez, Vesna
Seitz-Polski, Barbara
Lebrun-Frenay, Christine
Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
title Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
title_full Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
title_fullStr Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
title_full_unstemmed Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
title_short Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
title_sort kappa free light chains, soluble interleukin-2 receptor, and interleukin-6 help explore patients presenting with brain white matter hyperintensities
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990749/
https://www.ncbi.nlm.nih.gov/pubmed/35401550
http://dx.doi.org/10.3389/fimmu.2022.864133
work_keys_str_mv AT levrautmichael kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities
AT landescassandre kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities
AT mondotlydiane kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities
AT cohenmikael kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities
AT breschsaskia kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities
AT brglezvesna kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities
AT seitzpolskibarbara kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities
AT lebrunfrenaychristine kappafreelightchainssolubleinterleukin2receptorandinterleukin6helpexplorepatientspresentingwithbrainwhitematterhyperintensities